With fiber installation costs hitting $77,000 per home in some federally funded rural deployments, this microcap’s hybrid technology could help carriers connect far more households with the same grant money.…
Posts published in “Wall Street Wire”
Purple Biotech’s CAPTN-3 platform uses conditionally activated tri-specific antibody technology, part of a broader class of multispecific antibodies that has commanded $700 million+ upfront payments and multi-billion-dollar transactions across the…
Modern medicine has gotten remarkably good at developing drugs that work – and far less consistent at ensuring they’re used quickly and correctly in the real world. Needle fear remains…
For the biggest drug companies in the world, the holy grail in cancer treatment isn’t just shrinking tumors – it’s keeping them from coming back. Right now, the most commercially…
As investors look for new areas of growth in healthcare, women’s health has become a rising theme. One of the biggest and least discussed conditions in this space is osteoporosis,…
The cannabis industry may be approaching a pivotal regulatory moment. Major U.S. media outlets have reported that President Trump is considering an executive order that would direct federal agencies to…
As burn injuries rise from combat, disasters, and industrial accidents, one company’s enzymatic product has become so effective that the U.S. government is buying and stockpiling it for national emergencies.…
Past winners like Nalu Medical, BigHat, and Syncell later advanced to major partnerships and M&A deals. PolyPid’s (NASDAQ: PYPD) Phase 3 results now place it on similar footing In biotech,…
The Bottom Line: GLP-1 medicines reshaped obesity care by offering a biological alternative to surgery. MediWound (NASDAQ: MDWD) is applying that same idea to wound care. Its enzyme-based treatments can…
Antibiotic resistance may be creating one of the biggest crises and opportunities, in modern medicine, and companies like BiomX (NYSE:PHGE) could be sitting at the center of the solution. Using…